par Lee, Dae Hae;De Block, Christophe;Mathieu, Chantal;Pipeleers, Daniel;Gillard, Pieter;Keymeulen, Bart;Hilbrands, Robert;Ling, Zhidong;Van De Velde, Ursule;Jacobs-Tulleneers-Thevissen, Daniel;Maleux, Geert;Lapauw, Bruno;Crenier, Laurent
Référence Transplantation, 101, 9, page (2218-2227)
Publication Publié, 2017-09
Référence Transplantation, 101, 9, page (2218-2227)
Publication Publié, 2017-09
Article révisé par les pairs
Résumé : | BACKGROUND: Induction therapy with a T cell-depleting agent followed by mycophenolate mofetil and tacrolimus is presently the most frequently used immune suppression (IS) regimen in islet transplantation. This study assesses its safety and tolerability in nonuremic type 1 diabetic recipients. |